7 completed, 4 active not recruiting, 3 recruiting, 1 enrolling by invitation. 10 Phase 2, 8 Phase 3, 2 Phase 1.
Follow Praxis Precision Medicines: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks - Focal Epilepsy | Phase 3 | Active not recruiting | Praxis Precision Medicines | 300 | 2026-01-29 | 2026-08-03 |
| Clinical Trial of Vormatrigine in Adult Patients With Epilepsy vormatrogine - Epilepsy, Tonic-Clonic, Focal Seizure | Phase 3 | Enrolling by invitation | Praxis Precision Medicines | 700 | 2025-10-27 | 2026-08-03 |
| A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety 1mg elsunersen, 0.5mg elsunersen - Epileptic Encephalopathy, SCN2A Encephalopathy | Phase 3 | Recruiting | Praxis Precision Medicines | 40 | 2025-08-13 | 2026-08-03 |
| A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, Placebo - Developmental and Epileptic Encephalopathy 1 | Phase 3 | Active not recruiting | Praxis Precision Medicines | 160 | 2025-07-09 | 2026-08-04 |
| A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628 PRAX-628 - Healthy | Phase 1 | Completed | Praxis Precision Medicines | 16 | 2025-04-28 | 2026-08-03 |
| An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures 30mg PRAX-628 - Focal Onset Seizure, Primary Generalized Epilepsy | Phase 2 | Recruiting | Praxis Precision Medicines | 50 | 2025-01-10 | 2025-04-03 |
| Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1) 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo - Focal Seizure | Phase 2 / Phase 3 | Completed | Praxis Precision Medicines | 255 | 2024-12-11 | 2026-08-10 |
| Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET) 60 mg ulixacaltamide, Placebo - Essential Tremor | Phase 3 | Recruiting | Praxis Precision Medicines | 1000 | 2023-11-02 | 2026-10-06 |
| A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE) PRAX-562 - SCN2A Encephalopathy, SCN8A Encephalopathy | Phase 2 / Phase 3 | Active not recruiting | Praxis Precision Medicines | 77 | 2023-08-02 | 2026-01-29 |
| A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses, PRAX-222 - Optional Ascending Doses - SCN2A-DEE, Epilepsy | Phase 1 / Phase 2 | Active not recruiting | Praxis Precision Medicines | 60 | 2023-04-13 | 2026-08-03 |
| A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy SCN2A-DEE, Epilepsy | Completed | Praxis Precision Medicines | 5 | 2022-04-15 | 2024-01-10 | |
| A Clinical Trial of PRAX-114 in Participants With Essential Tremor 10 mg PRAX-114, 20 mg PRAX-114, and Placebo, 10 mg PRAX-114 or 20 mg PRAX-114 - Essential Tremor | Phase 2 | Withdrawn | Praxis Precision Medicines | 2022-04-05 | 2022-11-30 | |
| A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder 60 mg PRAX-114 or 40 mg PRAX-114, Placebo, 40 mg PRAX-114 - Post-traumatic Stress Disorder, Post Traumatic Stress Disorder | Phase 2 | Terminated | Praxis Precision Medicines | 11 | 2022-01-25 | 2022-12-01 |
| A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor 100 mg PRAX-944, 60 mg PRAX-944, Placebo - Essential Tremor | Phase 2 | Completed | Praxis Precision Medicines | 133 | 2021-10-14 | 2024-03-13 |
| A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder 10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114 - Major Depressive Disorder | Phase 2 | Completed | Praxis Precision Medicines | 110 | 2021-06-24 | 2022-08-19 |
| A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder PRAX-114, Placebo - Major Depressive Disorder | Phase 2 / Phase 3 | Completed | Praxis Precision Medicines | 216 | 2021-03-30 | 2022-07-21 |
| A Clinical Trial of PRAX-944 in Participants With Essential Tremor Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944, Part B: 120 mg PRAX-944 and Placebo - Essential Tremor | Phase 2 | Completed | Praxis Precision Medicines | 24 | 2020-03-03 | 2024-03-01 |
Epilepsy (5) · Essential Tremor (4) · Movement Disorders (4) · Seizures (4) · Depression (2) · Depressive Disorder (2) · Depressive Disorder, Major (2) · Mood Disorders (2) · Central Nervous System Diseases (1) · Epilepsies, Partial (1) · Epilepsy, Idiopathic Generalized (1) · Epilepsy, Tonic-Clonic (1) · Infantile Epileptic-Dyskinetic Encephalopathy (1) · Mental Disorders (1) · Stress Disorders, Post-Traumatic (1)
United States (16) · Australia (6) · Brazil (5) · Spain (4) · Italy (3) · Canada (2) · Germany (2) · Poland (2) · Israel (1) · Mexico (1) · New Zealand (1) · United Kingdom (1)